BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bristol-Myers Squibb Company (BMY) Announces Results Of Tender Offer And Intention To Redeem All Remaining 2006 Notes


10/19/2005 5:13:11 PM

NEW YORK, April 1 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb today announced the results of its cash tender offer to purchase any and all of its outstanding $2.5 billion aggregate principal amount 4.75% Notes due 2006, CUSIP No. 110122 AF 5 (the "Notes"). The offer commenced on Wednesday, March 23, 2005, and expired at 5 p.m., ET, Thursday, March 31, 2005.

The depositary agent, Global Bondholder Services Corporation, has informed the Company that an aggregate principal amount of $1,381,046,000 of the Notes was tendered in the offer.

Bristol-Myers Squibb today also issued a notice of mandatory redemption with respect to all Notes that remain outstanding following consummation of the tender offer. All Notes that remain outstanding following the consummation of the tender offer will be redeemed on Monday, May 2, 2005, at the previously disclosed redemption price of $1,014.06 per $1,000 principal amount.

Bristol-Myers Squibb Company is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Bristol-Myers Squibb

CONTACT: Media: Brian Henry, Communications, +1-609-252-3337, orbrian.henry@bms.com, or Investors: John Elicker, Investor Relations,+1-212-546-3775, or john.elicker@bms.com, both of Bristol-Myers Squibb


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->